TY - JOUR
T1 - Cohort study of cardiovascular safety of different COVID-19 vaccination doses among 46 million adults in England
AU - Ip, Samantha
AU - North, Teri-Louise
AU - Torabi, Fatemah
AU - Li, Yangfan
AU - Abbasizanjani, Hoda
AU - Akbari, Ashley
AU - Horne, Elsie M F
AU - Denholm, Rachel E
AU - Keene, Spencer
AU - Denaxas, Spiros
AU - Banerjee, Amitava
AU - Khunti, Kamlesh
AU - Sudlow, Cathie
AU - Whiteley, William N
AU - Sterne, Jonathan A C
AU - Wood, Angela M
AU - Walker, Venexia M
AU - CVD-COVID-UK/COVID-IMPACT Consortium
AU - Longitudinal Health and Wellbeing COVID-19 National Core Study
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/7/31
Y1 - 2024/7/31
N2 - The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs.
AB - The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events, and in rare cases, cardiovascular complications. There is less information about the effect of second and booster doses on cardiovascular diseases. Using longitudinal health records from 45.7 million adults in England between December 2020 and January 2022, our study compared the incidence of thrombotic and cardiovascular complications up to 26 weeks after first, second and booster doses of brands and combinations of COVID-19 vaccines used during the UK vaccination program with the incidence before or without the corresponding vaccination. The incidence of common arterial thrombotic events (mainly acute myocardial infarction and ischaemic stroke) was generally lower after each vaccine dose, brand and combination. Similarly, the incidence of common venous thrombotic events, (mainly pulmonary embolism and lower limb deep venous thrombosis) was lower after vaccination. There was a higher incidence of previously reported rare harms after vaccination: vaccine-induced thrombotic thrombocytopenia after first ChAdOx1 vaccination, and myocarditis and pericarditis after first, second and transiently after booster mRNA vaccination (BNT-162b2 and mRNA-1273). These findings support the wide uptake of future COVID-19 vaccination programs.
U2 - 10.1038/s41467-024-49634-x
DO - 10.1038/s41467-024-49634-x
M3 - Article (Academic Journal)
C2 - 39085208
SN - 0028-0836
VL - 15
JO - Nature
JF - Nature
IS - 1
M1 - 6085
ER -
